Mylan Inc. Aug. 12 announced that its subsidiary, Mylan Pharmaceuticals Inc., has launched its generic version of Uroxatral (alfuzosin hydrochloride extended-release) 10 milligram tablets.
Uroxatral treats the signs and symptoms of benign prostatic hyperplasia (enlarged prostate), the Pittsburgh-based company said.
According to IMS Health, Uroxatral tablets had U.S. sales of approximately $241 million for the 12 months ended June 30.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.